Navigation Links
Selexis and Neogenix Oncology Announce Agreement on Antibody Project
Date:9/22/2009

any dedicated to the development of innovative technologies and expert services that enable significant improvements in the time, effort, and costs required to develop and maintain high-performance mammalian cell lines used in the expression of pharmaceutically relevant proteins (i.e. targets, MAbs, rProteins). The company's core intellectual property portfolio is based on the discovery and application of novel DNA based elements that control the dynamic organization of chromatin within all mammalian cells - Selexis Genetic Elements(TM). Selexis has further developed platforms, to include: Selexis SUREtech Vectors(TM), Selexis SUREfection(TM) Selexis SURE Cell Line Development(TM) and Selexis INTEGRA-D2M(TM).

About Neogenix Oncology, Inc.

Founded in 2004, Neogenix Oncology, Inc., headquartered in Great Neck, NY, is a research-driven biopharmaceutical company that develops and commercializes innovative diagnostics and therapeutics for the management of solid tumors. Neogenix's pipeline is derived in part from the Hollinshead library of clinically tested vaccines, with the potential to develop products for a wide range of cancers, including colorectal, prostate, lung, ovarian, squamous, and others. The company conducts its research and development work in its laboratories in Great Neck, NY and in Rockville, MD. For more information, please visit the company's website at www.neogenixoncology.com.


'/>"/>
SOURCE Selexis SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Selexis and NKT Therapeutics Enter Into Research Services Agreement
2. Selexis Now Offering Rapid-Development of Human Cell Line With FDA Approval Pedigree
3. US Oncology Named to InformationWeek 500 as Top User of Business Technology
4. Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress
5. ESMO Online Innovation Helps the Oncology Community Share Knowledge and Enhance Practice
6. NCCN Holds Oncology Research Best Practices Conference
7. CBI Announces Multi-Stakeholder Collaboration Panel at Upcoming Effective Oncology Benefit Management Forum
8. DIA/FDA/PhRMA to Host Progression-Free Survival Oncology Workshop
9. Managing Myeloma Website Launches an Interactive Forum for Oncology Nurses, Wins 2009 Gold Hermes Creative Award for Site Overall
10. Light Sciences Oncology Expands Development of Novel Targeted Drug Aptocine(TM) For Prostate Conditions With Start-Up of Phase 2 BPH Trial
11. Arizona Oncology Opens Radiation Facility at Phoenix Baptist Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 (HealthDay News) -- Traveling through the same U.S. ... to three others within a four-hour time span, illustrating ... report shows. "The exposures in this report were ... an international terminal, highlighting the fact that measles is ... an infectious disease specialist at the U.S. Centers for ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 While countless companies ... do not realize the potential dangers of their purchase. Not ... prescription from a qualified doctor, but patients who buy hCG ... point that there is actually no real hCG present. Illegal ... where there are no safety standards and may contain unknown ...
(Date:12/17/2014)... Providence, RI (PRWEB) December 17, 2014 ... nationally recognize private practices that have made outstanding ... and in support and progression of private practice ... the American Physical Therapy Association. , On behalf ... DPT, OCS, owner and CEO of Performance accepted ...
(Date:12/17/2014)... WI (PRWEB) December 17, 2014 In ... Administrators and its Argus Claim Review division have ... of the most common ways savings are achieved on ... (TPA) attributes millions of dollars in savings to Argus ... in 2013. , As explained by Tom Doney, Cypress ...
(Date:12/17/2014)... Project Veritas is releasing a video ... MIT economist and Obamacare architect Jonathan Gruber to public ... the interview, which is being distributed on YouTube. , ... mislabeling in the Affordable Care Act in order to ... billion dollar per year tax grab. , “President Obama ...
Breaking Medicine News(10 mins):Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 2Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 3Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2
... Yosef Shiloh, Ph.D., a David and Inez Myers professor ... genetics and biochemistry in the Sackler School of Medicine ... Annual AACR G.H.A. Clowes Memorial Award for his studies ... genomic instability syndrome ataxia-telangiectasia (A-T). "Dr. Shiloh is ...
... that a novel form of personalized therapy that ... to fight tumors could treat metastatic melanoma and ... therapeutic approach against these and other cancers. ... body,s immune system to fight cancer. Immune cells, ...
... , MONDAY, Jan. 31 (HealthDay News) -- Two new studies ... cancer: melanoma, a deadly malignancy that first appears in the ... The first study, appearing in the Jan. 31 issue ... engineered immune cells from the patient to fight off the ...
... , MONDAY, Jan. 31 (HealthDay News) -- Daytime ... improves greatly after surgery for the disorder, according to a ... partially or completely blocked in short spurts, causing pauses in ... occur 30 times or more an hour, disrupting sleep. The ...
... stem cells in the gut relieves a potentially lethal complication ... published online on January 31 in the Journal of ... can cure diseases such as leukemia but it can also ... (GVHD). A group led by Takanori Teshima at Kyushu ...
... American Chemical Society (ACS) today launched the inaugural edition of ... online snapshot of the countless ways in which chemistry improves ... special video welcome from Nancy B. Jackson, Ph.D., who serves ... Sandia National Laboratories in New Mexico. Every month through ...
Cached Medicine News:Health News:Yosef Shiloh, Ph.D., receives the 51st Annual AACR G.H.A. Clowes Memorial Award 2Health News:Yosef Shiloh, Ph.D., receives the 51st Annual AACR G.H.A. Clowes Memorial Award 3Health News:Novel immune system-based gene therapy induces strong responses in metastatic melanoma, sarcoma 2Health News:New Therapies Offer Insight Into Battling Deadly Melanomas 2Health News:New Therapies Offer Insight Into Battling Deadly Melanomas 3Health News:Drowsiness May Decline After Apnea Surgery 2Health News:American Chemical Society unveils International Year of Chemistry virtual journal 2Health News:American Chemical Society unveils International Year of Chemistry virtual journal 3
(Date:12/17/2014)... -- IGI Laboratories, Inc. (NYSE MKT: IG; "IGI" or the ... $125 million aggregate principal amount of 3.75% Convertible Senior ... and sold only to qualified institutional buyers pursuant to ... amended (the "Securities Act"). The Notes bear ... payable semiannually in arrears on June 15 and December ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 17, ... (CTMC), and Integrated Clinical Trial Services, LLC (ICTS), ... for clinical trials announce that they have formed ... Services (i-CTMS). i-CTMS will provide a broad range ... biotechnology and medical device companies. i-CTMS ...
(Date:12/15/2014)... , December 15, 2014 ... Am 19. und 20. Februar sind ... Aegate SAFE MEDICINE ECOSYSTEM PARTNER PROGRAMM ™ ... zu besuchen. Diese Tagung soll ... die Möglichkeit geben, die neue profitablen Unternehmensdienstleistungen, ...
Breaking Medicine Technology:IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
... COLUMBUS, Ohio, Jan. 8 IntelligentMDx a developer and ... that verification studies of the IntelligentMDx BK Viral ... the Limit of Detection, linearity, specificity and reproducibility ... were determined. The data obtain agreed with internally ...
... have identified mutations in a gene that predict a high ... Although the researchers caution that further research is needed to ... or IKAROS, lead to leukemia relapse, the findings ... to assess the risk of treatment failure. By using a ...
Cached Medicine Technology:Verification Studies of IntelligentMDx's Proprietary Molecular Diagnostic Assay Process Have Been Completed 2Verification Studies of IntelligentMDx's Proprietary Molecular Diagnostic Assay Process Have Been Completed 3Gene Abnormality Found to Predict Childhood Leukemia Relapse 2Gene Abnormality Found to Predict Childhood Leukemia Relapse 3Gene Abnormality Found to Predict Childhood Leukemia Relapse 4Gene Abnormality Found to Predict Childhood Leukemia Relapse 5Gene Abnormality Found to Predict Childhood Leukemia Relapse 6
MPatch® is a topical adhesive wound dressing for the local management and control of bleeding from vascular access sites and percutaneous catheters....
The MYO-VAD is a novel cardiac support system with unique, life-saving features....
O-arm combines the best features of a traditional c-arm with an intra-operative 3D scannerfor unparalleled surgical imaging....
... full picture ,CardioPAL SAVI is the ... cial Intelligence, with a smart algorithm running ... on each device. The Diogenes algorithm continuously ... rate, rhythm, morphology, and p-wave abnormalities ...
Medicine Products: